Get ready to dive into a groundbreaking discovery that could revolutionize the skincare industry! The quest for effective anti-ageing solutions has led to an exciting breakthrough.
A collaborative effort between Inha University Hospital, Humantest Co, and B&B Korea has unveiled a game-changing technology known as "elastosome." This innovative approach addresses a long-standing challenge in cosmetic science: delivering bioactive proteins like epidermal growth factor (EGF) effectively through topical creams.
The research team focused on the stratum corneum, the outermost layer of our skin, which acts as a tightly packed barrier, often blocking beneficial molecules from reaching deeper layers. Traditional liposomes, though widely used, have limitations due to their rigidity, making it difficult for them to penetrate the skin deeply.
Enter the EGF FLEXIR-SOME particles, engineered to be highly flexible. These elastosomes, with their lipid bilayer and water-friendly core, are like soft stress balls compared to the rigid tennis ball-like liposomes. This extreme flexibility allows the vesicle to adapt and squeeze through the microscopic gaps in the stratum corneum, ensuring a more efficient delivery of encapsulated ingredients.
The final formulation combines EGF with dexpanthenol and nicotinamide mononucleotide (NMN) to create a powerful anti-ageing platform. But here's where it gets controversial: the team's technical specifications suggest that this new delivery system is not only stable but also highly efficient for commercial use.
Using advanced technology, they produced particles with an ideal diameter of 124.8 nanometres, perfect for cosmetic applications. The zeta potential, a measure of particle stability, was significantly higher than traditional liposomes, indicating a more stable and long-lasting formulation.
Laboratory tests using an artificial skin membrane revealed remarkable results. The elastosome formulation showed detectable penetration within just six hours, with absorption intensity increasing over a 24-hour period. In contrast, standard liposomes showed no absorption at all, highlighting the superiority of elastosome technology.
Clinical trials further supported these findings. In a two-week split-face study with 22 healthy Korean women, even a 2% concentration of elastosome cream delivered impressive results. Eye area elasticity increased by nearly 10%, and wrinkle depth decreased by almost 9%. The Skin Age Index, a measure of overall skin health, improved by over 14% for the 2% formulation and by 10.49% for the 8% formulation.
The study also revealed significant improvements in hydration and barrier repair. A single application of the cream increased skin moisture by an astonishing 448.52%, and it reduced transepidermal water loss by over 30% after skin irritation. Hyperpigmentation and melasma also showed noticeable improvements.
And this is the part most people miss: the researchers conducted rigorous skin irritation tests on 32 subjects, and both the 2% and 8% formulations scored perfectly safe, with no reported side effects or allergic reactions.
While the results are promising, the researchers acknowledge the need for further research to determine the optimal ingredient concentration and to test the formulation on a more diverse range of ethnic populations.
The future of the EGF platform looks bright, and this advanced elastosome delivery system has the potential to become a multifunctional cosmetic powerhouse. It's an exciting development that could offer a more effective and holistic approach to skincare.
What do you think? Do you find this breakthrough as exciting as we do? Share your thoughts and let's discuss the potential impact of elastosome technology on the skincare industry!
